gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Dec 2016.

Transforming growth factor, beta 2

TGF-beta 2
Top mentioned proteins: TGF-beta, CAN, HAD, ACID, IL-1beta
Papers on TGF-beta 2
Andrographolide suppresses epithelial mesenchymal transition by inhibition of MAPK signalling pathway in lens epithelial cells.
Vasavada et al., Ahmadābād, India. In J Biosci, Jun 2015
Initially the LECs were treated with growth factors (TGF-beta 2 and bFGF) to induce EMT.
MicroRNA-26a modulates transforming growth factor beta-1-induced proliferation in human fetal lung fibroblasts.
Wen et al., Chengdu, China. In Biochem Biophys Res Commun, 2014
Furthermore, we showed that miR-26a mediated a TGF-beta 2-TGF-beta 1 feedback loop and inhibited TGF-beta R I activation.
Phase I trial of TGF-beta 2 antisense GM-CSF gene-modified autologous tumor cell (TAG) vaccine.
Nemunaitis et al., Dallas, United States. In Clin Cancer Res, 2011
PURPOSE: On the basis of the hypothesis that the combined expression of immunostimulatory granulocyte macrophage colony stimulating factor (GM-CSF) and antitumor suppressor TGF-β2 antisense (AS) transgenes can break tolerance and stimulate immune responses to cancer-associated antigens, we constructed an expression plasmid [the tumor-associated glycoprotein (TAG) plasmid] that coexpresses GM-CSF and TGF-β2 AS nucleotide sequences and which was incorporated into an autologous whole-cell vaccine.
Antifibrotic medication using a combination of N-acetyl-L-cystein (NAC) and ACE inhibitors can prevent the recurrence of Dupuytren's disease.
Vogt et al., Hannover, Germany. In Med Hypotheses, 2009
A number of in vitro experiments have been assessed the blockade of TGF-beta1 and TGF-beta 2. Clinically, a number of antifibrotic agents are available such as N-acetyl-L-cysteins (NAC) as well as angiotensin-converting enzyme (ACE) inhibitors or AT II antagonists.
TGF-beta signaling and collagen deposition in chronic rhinosinusitis.
Bachert et al., Gent, Belgium. In J Allergy Clin Immunol, 2009
Only TGF-beta 2 protein was found higher in CRSwNP versus controls.
Targeted tumor therapy with the TGF-beta 2 antisense compound AP 12009.
Jachimczak et al., Regensburg, Germany. In Cytokine Growth Factor Rev, 2006
We have developed a new immunotherapeutic approach for the treatment of malignant tumors based on the specific inhibition of TGF-beta2 by the antisense oligodeoxynucleotide AP 12009.
Comprehensive evaluation of ureteral healing after electrosurgical endopyelotomy in a porcine model: original report and review of the literature.
Clayman et al., São Paulo, Brazil. In J Urol, 2004
The other half was frozen and reverse transcriptase-polymerase chain reaction was performed to measure steady state levels of epidermal growth factor, transforming growth factor (TGF)-alpha, TGF-beta 1, TGF-beta 2, TGF-beta 3, keratinocyte growth factor, vascular endothelial growth factor, insulin-like growth factor, platelet derived growth factor, collagen type 1, integrin and fibronectin transcript expression.
[Control of wound healing after glaucoma surgery. Effect and inhibition of the growth factor TGF-beta].
Grehn et al., Würzburg, Germany. In Ophthalmologe, 2002
Among the growth factors, TGF-beta 2 represents an important stimulant of scarring with a key regulatory function.
[Multiple sclerosis. Current review of failed and discontinued clinical trials of drug treatment].
Hohlfeld et al., Martinsried, Germany. In Nervenarzt, 2000
In addition to a description of the immunobiological background, studies on the immunosuppressive agents linomide, deoxyspergualin, sulfasalazine and cladribine, trials for the cytokines interleukin-10 and TGF-beta 2, the studies on remyelination by intravenous immunoglobulins (IVIg), oral tolerance, and extracorporeal photopheresis are discussed.
[The modern approach to wound treatment].
Komarcević, Novi Sad, Serbia. In Med Pregl, 2000
TGF-beta 3 isoform has recently been described and may have an inhibitory function on scar formation by being a natural antagonist to the TGF-beta 1 and TGF-beta 2 isoforms.
Deactivation of macrophages by transforming growth factor-beta.
Nathan et al., New York City, United States. In Nature, 1988
Among 11 such factors, two proteins that are 71% similar proved to be potent macrophage deactivators: these are transforming growth factor-beta 1 (TGF-beta 1) and TGF-beta 2.
Mesoderm induction in amphibians: the role of TGF-beta 2-like factors.
Dawid et al., Bethesda, United States. In Science, 1988
Transforming growth factor beta 2 (TGF-beta 2), but not TGF-beta 1, was active in alpha-actin induction, while addition of fibroblast growth factor had a small synergistic effect.
Cell adhesion protein receptors as targets for transforming growth factor-beta action.
Massagué et al., Worcester, United States. In Cell, 1987
Treatment of cells with either form of TGF-beta, TGF-beta 1, or TGF-beta 2, increases the rate of receptor synthesis and the level of receptors on the cell surface.
Two forms of transforming growth factor-beta distinguished by multipotential haematopoietic progenitor cells.
Massagué et al., Worcester, United States. In Nature, 1987
Two distinct homodimeric TGF-beta polypeptides, TGF-beta 1 and TGF-beta 2 have been identified which show approximately 70% amino-acid sequence similarity.
The transforming growth factor-beta system, a complex pattern of cross-reactive ligands and receptors.
Massagué et al., In Cell, 1987
A new homodimer form of transforming growth factor-beta (TGF-beta), TGF-beta 2, has been identified in porcine blood platelets.
share on facebooktweetadd +1mail to friends